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Introduction
Platelet plug formation is a primary hemostatic reaction that prevents bleeding. Once plasma von Willebrand factor (VWF) is immobilized on the subendothelial matrix at the site of a vascular injury, VWF is stretched by high shear stress. This exposes a cryptic GPIb-binding site, thereby increasing VWF's affinity for platelet glycoprotein (GP) Ib [1, 2] . Platelets roll and adhere to VWF via the GPIb receptor, and the 'inside-out' signal affects the GPIIb-IIIa conformation, leading to firm platelet adhesion and aggregation. This initial interaction between VWF and GPIb is an important event in in vivo hemostasis.
VWF is a multifunctional protein composed of D 0 , D, A1, A2, A3, C1, C2, C3, C4, C5, C6 and CK domains [3] , and each domain has a distinct function. The A1 and A3 domains constitute major binding sites for GPIb and collagen, respectively. The C4 domain contains the RGD sequence that binds to GPIIb-IIIa (integrin a IIb b 3 ). In in vitro assays, the VWF cofactors ristocetin, botrocetin and bitiscetin have been used to evaluate the functional activities of VWF and GPIb. These cofactors are nonphysiologic inducers, but are useful for the subdiagnosis of von Willebrand disease (VWD) caused by quantitative or qualitative defects in VWF, and Bernard-Soulier syndrome caused by GPIb deficiency. Ristocetin is a superior standard reagent for laboratory tests but has some limitations; for example, a higher concentration of ristocetin induces the flocculation of fibrinogen, indicating that ristocetin is not specific to VWF but interacts with other proteins [4, 5] . Although ristocetin's mechanism of action remains unclear, we know that its positive charge reverses the negatively charged groups on the VWF A1 domain and GPIb. This reversal reduces the static repulsion between them, and would bring VWF much closer to GPIb [6, 7] .
Botrocetin and bitiscetin are derived from the venoms of Bothrops jararaca and Bitis arietans, respectively [8] [9] [10] [11] . They harbor a C-type lectin-like motif, and proteins of this family are typically composed of disulfide-linked heterodimers of a and b subunits [12, 13] . Both botrocetin and bitiscetin bind specifically to the VWF A1 domain, and this complex shows high affinity for GPIb [14, 15] . Given that they are highly specific to VWF, botrocetin and bitiscetin are considered to be superior diagnostic reagents. Furthermore, their binding specificities towards VWF are attractive, because anti-VWF drugs are not abundant as compared with antiplatelet drugs [16] .
As the regulation of the initial contact between VWF and GPIb is crucial for preventing pathologic thrombus formation, we attempted to interfere with the VWF-GPIb axis by modifying botrocetin's structure, with the advantage of its VWF-binding activity. To obtain structurally homogeneous and manipulable proteins, we cloned botrocetin cDNAs. In a previous study [17] , we obtained cDNAs highly similar to those of botrocetin, designated as botrocetin-2 (Bot2), and the recombinant protein (rBot2) showed effects that were extremely similar to those of native botrocetin. Using Bot2 cDNA, we attempted to design a mutant rBot2 that binds to VWF and blocks platelet binding. In the present study, we identified essential residues of Bot2 for binding to VWF and GPIb. Using these findings, we succeeded in expressing a site-directed mutant rBot2 that binds specifically to VWF and inhibits interaction with GPIb.
Materials and methods

Materials
Botrocetin and bitiscetin were purified from crude venom as previously described [10, 12] . The anti-VWF mAb VW40-1 and the anti-botrocetin mAbs BCT4-3 and 107-3 [18] were generous gifts from Takara Bio (Kusatsu, Japan), and biotinylated BCT107-3 was prepared with a conventional method. The anti-VWF mAb NMC4 was prepared as previously described [19] . All reagents used were of biochemical or molecular biology grade, and were purchased from New England BioLabs (Beverly, MA, USA), Toyobo (Osaka, Japan), Wako Pure Chemical Industries (Osaka, Japan), and Nacalai Tesque (Kyoto, Japan), unless otherwise noted. Human 293T cells were purchased from the RIKEN Bioresource Center (Tsukuba, Japan).
Construction of mutant Bot2 cDNA cDNAs of Bot2 a and b subunits were ligated into a pTandem-1 (Novagen, Madison, WI, USA), and point mutations were introduced with the QuickChange II kit (Agilent Technologies, Santa Clara, CA, USA) as previously described [17] . Briefly, PCR primers containing the desired codon (coding Ala or Glu) in the middle position were designed and subjected to PCR with PfuUltra HF DNA polymerase. After digestion with DpnI, products were introduced into XL1-Blue competent cells. Several colonies were selected and subjected to plasmid DNA purification with a mini-prep kit (Qiagen, Tokyo, Japan), and this was followed by DNA sequence verification. DNA sequencing was performed with a BigDye terminator cycle sequencing kit (Applied Biosystems Japan, Tokyo, Japan) and a Genetic Analyzer 3130 (Applied Biosystems), according to the manufacturer's instructions.
Recombinant protein expression
Plasmids containing the mutated cDNA were amplified and purified with a QIA filter plasmid maxi kit (Qiagen). The 293T cells were used for rBot2 expression because of their ability to proliferate stably. The 293T cells were spread in 10 90-mm Petri dishes by the use of Dulbecco's modified Eagle's medium (DMEM) (Gibco Life Technologies, Tokyo, Japan) supplemented with 10% fetal bovine serum at 37°C under 5% CO 2 . Cells at 50-60% confluent growth were transfected with each plasmid by the use of GeneJuice (Novagen) and OPTI-MEM (Gibco Life Technologies), according to the manufacturer's instructions. Cells were grown in DMEM supplemented with 10% fetal bovine serum for 72 h. The culture medium was centrifuged at 1500 9 g for 10 min, and the supernatant was mixed with 0.5% protease inhibitor cocktail (Nacalai Tesque). This was then subjected to column chromatography or stored at À 70°C until further use.
Purification of recombinant protein mAb BCT4-3 or mAb BCT107-3 against botrocetin was conjugated with BrCN-activated agarose (Sigma Aldrich, St Louis, MO, USA). Culture medium was applied to an anti-botrocetin mAb column at 25°C, and the column was washed thoroughly with Tris-buffered saline (TBS) (150 mM NaCl, 10 mM Tris-HCl [pH 7.5]) until the eluate A 280 nm returned to baseline. The column-bound fraction was eluted with 100 mM Gly-HCl buffer (pH 2.7). Eluates were immediately neutralized with 200 mM Gly-NaOH buffer (pH 10.0), and peak fractions at A 280 nm were collected and concentrated with Amicon Ultra (Millipore, Billerica, MA, USA). The protein concentration was determined with a BCA protein assay reagent (Pierce, Rockford, IL, USA) with bovine serum albumin (BSA) as a standard. Approximately 1 lg of each rBot2 was examined by SDS-PAGE with 15% gel under nonreduced and reduced conditions.
Platelet agglutination assay
After informed consent had been obtained, blood was drawn from healthy donors and deposited in blood-collection vacuum tubes that contained a 1 : 10 volume of 3.4% sodium citrate. Citrated blood was centrifuged at 100 9 g for 10 min, and platelet-rich plasma (PRP) was collected. The remaining blood was further centrifuged at 1000 9 g for 15 min to obtain platelet-poor plasma (PPP). PRP (250 lL) containing 3 9 10 5 platelets lL -1 was stirred in a small cuvette at 37°C for 2 min on an aggregometer (Model PT-2; Mebanics, Yokohama, Japan). PRP light transmission after addition of 5 lL of test solution containing rBot2 (final, 0.5-5.0 lg mL
À1
), ristocetin (final, 1.5 mg mL
), equine collagen type 1 (final, 2.0 lg mL
) or ADP (final, 6 lM) was monitored with PPP as a reference.
For the shear stress-induced platelet aggregation (SIPA) assay, 400 lL of PRP was applied to an argon laser-assisted cone platelet aggregometer (Toray Medical, Tokyo, Japan). Platelet aggregation was continuously monitored in the presence or absence of mutant rBot2 (0.8-3.6 lg mL À1 ) or anti-VWF mAb NMC4
(10 lg mL À1 ) by recording the intensity of the light transmitted through the platelet suspension at a constant shear rate of 108 dyne cm -2 for 6 min [20] . All experiments were performed within 3 h after blood collection.
Measurement of antithrombogenicity in the flow
To assess the effects of rBot2 mutants on the thrombogenicity of whole blood, a total thrombus-formation analysis system (T-TAS) (Fujimori Kogyo, Tokyo, Japan) was used. The T-TAS is a microchip-based flow-chamber system developed for assessment of platelet thrombus formation under flow conditions [21, 22] . Whole normal blood anticoagulated by hirudin (25 lg mL À1 ) was preincubated with or without rBot2 mutants at 37°C for 2 min, and subjected to flow into a type I collagen-coated chip at an initial shear rate of 2000 S
À1
. As a thrombus gradually forms, it blocks the flow, resulting in an increase in flow pressure.
VWF-binding assay
For dot blot analysis, 100 lL of TBS containing 0.5-4 lg of either rBot2 or bitiscetin was adsorbed onto a polyvinylidene difluoride (PVDF) membrane (Millipore) under vacuum with a dot-blotter apparatus (Gibco Life Technologies). The membrane was soaked in TBS containing 0.05% Tween-20 (T-TBS) at 4°C overnight, incubated with plasma diluted 1 : 20 in T-TBS for 90 min at 25°C, and then incubated with horseradish peroxidase (HRP)-conjugated anti-VWF antibody (1 : 2000; Dako, Kyoto, Japan) for 60 min. After washing with T-TBS, the HRP reaction was performed with a SigmaFast diaminobenzidine kit (Sigma-Aldrich). The presence of rBot2 proteins on the membrane was detected with a biotinylated anti-botrocetin mAb (BCT107-3: 1 : 1000) and HRP-conjugated streptavidin (1 : 2000; Vector Laboratories, San Mateo, CA, USA).
For ELISA, ELISA module plates (Nunc, Roskilde, Denmark) were coated with 50 lL of 50 mM bicarbonate buffer solution (pH 9.5) containing 10 lg mL 
Glycocalicin (GC)-binding assay
GC was used instead of GPIb, because GPIb is an insoluble membrane protein but GC is a soluble fraction of the GPIb extracellular domain, which acts as a receptor for VWF [23] . GC and biotinylated GC were prepared as previously described [15] . For the GC-binding assay, an ELISA plate preincubated with VWF solution (as described above) was incubated with 50 lL of rBot2 solution (0.5 lg mL À1 in B-TBS) in the presence or absence of biotinylated GC (2 lg mL À1 in B-TBS) at 25°C for 90 min. After washing with T-TBS, HRP-conjugated streptavidin (1 : 2000) was used for the detection of bound GC. The HRP reaction was measured as described above.
Three-dimensional (3D) structure modeling
The 3D structure of Bot2 was constructed by a homology modeling technique based on the 3D structure of botrocetin (Protein Data Bank entry 1u0n [24] ) with the SWISS-MODEL program [25, 26] . Molecular graphic images were produced with the UCSF CHIMERA package from the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco (supported by NIH P41 RR-01081) [27] .
Statistical analysis
The binding of rBot2 mutants to VWF and GC binding to the VWF-rBot2 complex were expressed as relative binding ratio (mean AE standard error of the mean) of duplicate or triplicate experiments, with 100% binding of wild-type rBot2 as a reference. Statistical analysis (unpaired t-test) was performed and graphs were obtained with GRAPHPAD PRISM v.7 (GraphPad, San Diego, CA, USA), and a P-value of < 0.05 was considered to be statistically significant.
Results
We have previously reported several important rBot2 residues that induce platelet agglutination, determined by using Ala-scanning mutagenesis on the charged residues in rBot2 [17] . In that study, we used the concentrated culture medium of transfected cells as crude rBot2 preparations. In the present study, each rBot2 protein was purified to homogeneity on an anti-botrocetin antibody column (Fig. 1A) . Single-substitution rBot2 mutants (Aspb70Ala, Argb115Ala, and Lysb117Ala) showed no platelet agglutination-inducing activity at 0.5 lg mL À1 , but did at 2 lg mL À1 (Fig. 1B) . Double substitution (Argb115Ala/Lysb117Ala) resulted in no platelet agglutination-inducing activity even at 2 lg mL À1 , indicating an additive effect of the two substitutions.
To determine whether or not the decreased platelet agglutination of the mutant rBot2 was attributable to the loss of VWF-binding activity, the VWF-binding activity of mutant rBot2 was assessed with a dot blot analysis and ELISA. Each protein was dot-blotted on a PVDF membrane, and this was followed by incubation with VWF solution. The three mutants Glua107Ala, Aspb70Ala and Aspb88Ala showed decreased binding to VWF as compared with the other mutants (Fig. 2) . In a separate experiment, wherein VWF was immobilized on an ELISA plate and rBot2 binding to the captured VWF was assessed, the Aspb70Ala and Aspb88Ala mutants showed decreased binding to VWF (Fig. 3A) . As the mAb BCT107-3, used for rBot2 detection, does not interfere with botrocetin-VWF binding [18] and binds to all rBot2 mutants (Fig. 2) , decreased binding of the Aspb70 mutant to VWF is not attributable to the decreased affinity of the mAb resulting from the mutation. The difference between the dot blot analysis and ELISA results suggests that direct absorption of rBot2 on the PVDF membrane affected the configuration of some mutant rBot2s and decreased the interaction with the VWF molecule. Other rBot2 mutants showed binding to VWF that was comparable to that shown by wild-type rBot2.
To confirm the GPIb-binding activity of the VWFrBot2 complex, rBot2 was incubated with biotin-conjugated GC in the VWF-captured ELISA plate, and then incubated with HRP-conjugated streptavidin solution. All mutant rBot2s showed decreased binding of GC. In particular, rBot2 with Argb115Ala and/or Lysb117Ala and rBot2 with Aspb70Ala showed weak binding (Fig. 3B) .
Mutants with Argb115Ala, Lysb117Ala or both showed normal binding to VWF (Figs 2 and 3A) but decreased GC binding. Assuming that Argb115 and Lysb117 are important residues for binding to GPIb, these basic residues may interact with negatively charged GPIb residues. We further substituted these basic residues with acidic Glu or Asp residues, solely or dually, expecting static repulsion. Mutant rBot2s with countercharged residue(s) showed reduced GC binding without any observed change in VWF binding (Fig. 4A,B) . In the case of the platelet agglutination assay, rBot2 with Lysb117Glu gradually induced platelet agglutination at 0.5 lg mL
À1
, whereas the mutant with Argb115Glu and the mutant with the double substitution Argb115Glu/Lysb117Glu had no platelet-agglutinating activity at 5.0 lg mL À1 (Fig. 4C ). In addition, these mutant proteins showed an inhibitory effect on ristocetin-induced platelet aggregation (Fig. 5A ).
In particular, rBot2 with a double substitution (Argb115-Glu/Lysb117Glu) showed a strong inhibitory effect even at a concentration of 0.5 lg mL
. This pretreatment effect of the mutant rBot2 (Argb115Glu/Lysb117Glu) had no influence on collagen-induced (Fig. 5B) or ADPinduced platelet aggregation (data not shown).
The effects of these mutants on SIPA were investigated (Fig. 6A) . The anti-VWF mAb NMC4 clearly inhibited SIPA, as described previously [28] . When the SIPA assay was performed in the presence of the mutant rBot2 (Argb115Glu/Lysb117Glu), platelet aggregation was affected in a concentration-dependent manner. In contrast, the rBot2 with Argb70Ala showed enhanced SIPA (data not shown).
The antithrombotic effect of rBot2 mutants was examined with T-TAS by use of a collagen-coated microchip (Fig. 6B) . In the absence of rBot2, blood flow was gradually blocked as the thrombus grew with the increase in flow pressure. The time span until the flow pressure exceeds 60 kPa is the occlusion time that indicates the completion of thrombus formation [21] . Thrombus formation was significantly inhibited in the presence of mutant rBot2 (Argb115Glu/Lysb117Glu) at 1-2 lg mL À1 .
Discussion
Given that the interaction between VWF and GPIb is a prerequisite for hemostatic plug formation, regulating this initial event is an effective antithrombotic strategy. Botrocetin has been used as a specific tool for study of the VWF-GPIb interaction in vitro. Although botrocetin is yet to be routinely used as a diagnostic reagent, its crystal structure and mechanism of action have been elucidated in detail [24, 29] . The VWF-botrocetin complex provides a cooperative binding site for GPIb that enhances affinity for GPIb, thereby resulting in platelet agglutination. Thus, botrocetin is a unique snake venom protein targeting VWF. The present study was designed on the basis of botrocetin's VWF-binding capacity. We tried to construct a dominant-negative mutant rBot2 that binds to VWF, but has an inhibitory effect on platelet agglutination. First, we identified charged residues of Bot2 that were required for binding to VWF and GPIb. Homology modeling of the ternary Bot2-VWF A1 domain-GPIba complex indicated that Aspb70, Glua107 and Aspb88 of Bot2 are present in the VWF A1 domain-binding interface [17] . Although rBot2 with Argb70Ala showed reduced binding to VWF, a single substitution was insufficient to eliminate all VWF-binding activity; in fact, rBot2 with Argb70Ala showed platelet agglutination-inducing activity at a high concentration. Several residues of botrocetin interact with VWF, and multiple interactions may be involved in VWF binding [24, 30] . It will also be interesting to clarify whether rBot2 can bind to the mutant VWFs found in VWD individuals, such as in those with type 2M VWD, which show a normal multimer pattern but reduced GPIb binding in the presence of ristocetin or botrocetin [31, 32] . Several mutations have been found in the VWFs from type 2M VWD individuals, such as missense (Ser1285Phe, Phe1369Ile, Asn1421Lys, and Ile1425Phe) or deletion (Arg1392-Gln1492) mutations [31] [32] [33] [34] . These mutations in the A1 domain affect the binding sites for ristocetin, botrocetin, and/or GPIb. As the basic residues Arg1392, Arg1395, Arg1399 and Lys1430 in the A1 domain have been elucidated as important residues for binding to botrocetin [14] , mutant VWFs of type 2M VWD individuals would show either decreased rBot2 binding or normal rBot2 binding with decreased platelet binding. Conversely, rBot2 mutants have the potential to show specific binding to certain types of VWF mutant. The binding of GC to the VWF-rBot2 complex was compared with 100% binding of wild-type rBot2 as reference. All mutant rBot2s showed decreased binding activity towards GC; Aspb70Ala, Argb115Ala, Lysb117Ala and Argb115Ala/Lysb117Ala mutants, in particular, showed very weak binding. (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001).
For binding to GPIb, Arg115 and Lys117 in the b subunit of rBot2 were identified as key residues. We postulated that these basic residues would interact with acidic residue(s) of GPIb. Homology modeling of the Bot2-VWFA1-GPIba ternary complex suggested a static interaction between Argb115 and Lysb117 of Bot2 and Asp222 of GPIba (Fig. 7) . Double substitution of both basic residues with Glu residues on rBot2 did not result in either GPIb binding or platelet agglutination; however, VWF-binding activity remained unchanged. As expected, this mutation had an inhibitory effect on ristocetininduced or shear stress-induced platelet aggregation and on thrombus formation under flow conditions, suggesting electrostatic repulsion between mutant rBot2 and GPIb, owing to the negatively charged residues (Fig. 8) . There is a possibility that these substitutions influence the conformation of the GPIb-binding site of rBot2; however, we assume that the static effect between them is a major cause of inhibition, because the same results were obtained for the rBot2 with Argb115 and Lysb117 substituted with Asp (data not shown).
Several mAbs against GPIb or VWF have been established, some of which have inhibitory effects on GPIbdependent or VWF-dependent platelet agglutination [19, 35] . However, their use as antithrombotic agents poses challenges, owing to the size of the IgG. Furthermore, the functional blockage of GPIb with antibodies or binding proteins is difficult, partly because GPIb is a membrane receptor that mediates signal transduction to the cytoplasm. GPIb stimulation by simple binding may induce an internal conformational change that provokes signal transduction. Recently, Li et al. [36] reported that anfibatide (agkisacucetin), a GPIb complex antagonist purified from Agkistrodon acutus venom, inhibits platelet adhesion and thrombus formation both in vitro and in vivo in a murine model. Anfibatide does not stimulate signaling pathways downstream of GPIb, and it also inhibits residual thrombosis in VWF-deficient mice, suggesting that, in addition to its inhibitory effect on the VWF-GPIb interaction, anfibatide has an antithrombotic effect.
From the standpoint of VWF, only the artificially humanized nanobody ALX-0081 (caplacizumab), an approximately 25-kDa bivalent IgG heavy chain targeting the VWF A1 domain [37, 38] , and the anti-VWF aptamer ARC1779 [39] , an oligonucleotide targeting the A1 domain, have been identified as superior antithrombotic drugs, and clinical trials on these are underway [40, 41] . Although several snake venom proteins have been found to bind to VWF, no snake venom protein that binds to VWF and inhibits GPIb binding has been reported to date [42] . The present mutant rBot2 (Argb115Glu/Lysb117Glu) is a novel probe used as a specific inhibitor of the VWFGPIb interaction for studying hemostatic mechanisms. In an ex vivo experiment using whole blood under flow conditions, this mutant rBot2 had a suppressive effect on thrombus formation on the collagen surface. The concentration of the mutant rBot2 that is sufficient to interfere with GPIb binding is approximately 2 lg mL À1 (0.09 lM), which is comparable to that of VWF (A1), i.e. 10-20 lg mL À1 (0.04-0.08 lM as a subunit) in plasma.
This suggests that rBot2 does not form an oligomer and that it almost equivalently binds to VWF subunits. Although we are yet to perform an infusion study on mutated rBot2 by using thrombus model animals to evaluate its effects in vivo, these data suggest the potential of mutant rBot2 as an antithrombotic reagent that specifically blocks VWF function. As rBot2s are expressed in cultured cells (293T cells), there is no toxicity to the cells, but botrocetin has been used for mimicking of thrombotic thrombocytopenic purpura in an animal model as a platelet agglutination inducer [43] . It is essential to confirm the non-toxicity of the protein in vivo. The immunologic response would also reject the repeatedly administered rBot2 mutant. There is a possibility that the mutant rBot2 will only be effective in one-shot therapy or under immunosuppressive conditions. Further analyses using an in vivo or ex vivo thrombotic system are warranted to determine whether this rBot2 mutant is safe and applicable as an antithrombotic drug. By mimicking natural biological products, novel reagents that are useful for diagnosis and therapeutic applications may be obtained by protein engineering. As several immunoglobulins and antibiotics from animals have been selected and administered as medicines, animal toxins have remained attractive sources of useful bioactive substances.
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